PD1 / PDL1 Blockade In Mouse Tumor Syngeneic Models

Combinatory approaches in immuno-oncology with immune checkpoint inhibitors including anti-PD1 / PDL1 or anti-CTLA4 therapeutic antibodies is an active field of investigation. In order to evaluate potential synergistic effect of novel chemotherapeutic agents, immunostimulatory compounds, etc., we characterized the clinical response to anti-PD1 and anti-PDL1 in immunocompetent animal models. Ancillary studies including FACS analysis, RT-qPCR can provide support to delineate mechanism of actions of a drug candidate and can also support the identification of novel predictive biomarkers.

Differential sensitivity to anti-PD1 and anti-PDL1 antibodies in two mouse syngeneic tumor models.Representation of individual tumor growth from MC38 and CT26 tumor bearing mice exposed to anti-PD1 or anti-PDL1 antibodies or only treated with the vehicle. MC38 mouse tumor model responds to PD1 / PDL1 axis blockade while CT26 model appears to not be sensitive.